April 25, 2024
Bristol Myers Squibb’s psoriasis therapy Sotyktu (deucravacitinib) is braced for a downward price adjustment under the cost-effectiveness assessment (CEA) scheme, according to the health ministry’s appraisal results approved on April 24. An oral tyrosine kinase 2 (TYK2) inhibitor, Sotyktu joined...read more